Opinion

Video

EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma

Author(s):

Joseph Mikhael, MD

Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.

Video content above is prompted by the following question:

  1. Discuss the data presented at EHA 2024 on the efficacy and safety of teclistimab in patients with relapsed/refractory multiple myeloma (RRMM) with high-risk features: a subgroup analysis of the phase 1/2 MajesTEC-1 study. (Abstract)
    1. What was the objective of the subgroup analysis of this study?
    2. How was this study designed/what methodology was used?
    3. What results were presented?
      1. N=165
    4. N=24 aged ≥75 years
    5. N=20 ISS stage III
    6. N=38 high-risk cytogenetics
    7. N=28 extramedullary disease
    8. N=18 bone marrow plasma cells
    9. N=50 penta-drug refractory
      1. Median follow up ~30 months across subgroups
      2. Objective Response Rate (ORR)
      3. Median duration of response (mDOR)
      4. Safety
Related Videos
Related Content
Kirollos Hanna, PharmD
January 25th 2025

Dr Kirollos Hanna: An Argument for Outpatient Bispecific Antibody Delivery

Kyle Munz Kirollos Hanna, PharmD
Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
Robert Rifkin, MD | Image credit: Rocky Mountain Cancer Centers
January 22nd 2025

Study of Prophylactic Tocilizumab May Soon Add Talquetamab Arm

Luke Halpern Laura Joszt, MA
Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com
January 21st 2025

High Infection Risk in MM: Insights From the Pre-Immunotherapy Era

Kyle Munz
Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.
MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com
January 13th 2025

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

Kyle Munz
This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.
Woman wearing Enfuse injector | image credit: Enable Injections
January 9th 2025

Subcutaneous Isatuximab Meets Primary End Points in Phase 3 Study for MM

Mary Caffrey
If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.
mRNA vaccines can boost T cell responses | image credit: myskin - stock.adobe.com
January 9th 2025

Study Advocates Immunological Value of COVID-19 Vaccination in MM

Kyle Munz
Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA vaccines could bolster immunity in this vulnerable population.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo